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Background: In 2008, a national human papillomavirus (HPV) immunisation programme began in Scotland for 12–13 year old
females with a three-year catch-up campaign for those under the age of 18. Since 2008, three-dose uptake of bivalent vaccine in
the routine cohort aged 12–13 has exceeded 90% annually, while in the catch-up cohort overall uptake is 66%.
Methods: To monitor the impact of HPV immunisation, a programme of national surveillance was established (pre and
post introduction) which included yearly sampling and HPV genotyping of women attending for cervical screening at age 20. By
linking individual vaccination, screening and HPV testing records, we aim to determine the impact of the immunisation
programme on circulating type-specific HPV infection particularly for four outcomes: (i) the vaccine types HPV 16 or 18 (ii) types
considered to be associated with cross-protection: HPV 31, 33 or 45; (iii) all other high-risk types and (iv) any HPV.
Results: From a total of 4679 samples tested, we demonstrate that three doses (n¼ 1100) of bivalent vaccine are associated with a
significant reduction in prevalence of HPV 16 and 18 from 29.8% (95% confidence interval 28.3, 31.3%) to 13.6% (95% confidence
interval 11.7, 15.8%). The data also suggest cross-protection against HPV 31, 33 and 45. HPV 51 and 56 emerged as the most
prevalent (10.5% and 9.6%, respectively) non-vaccine high-risk types in those vaccinated, but at lower rates than HPV 16 (25.9%) in
those unvaccinated.
Conclusions: This data demonstrate the positive impact of bivalent vaccination on the prevalence of HPV 16, 18, 31, 33 and 45 in
the target population and is encouraging for countries which have achieved high-vaccine uptake.
It has been estimated that 15–20% of all human cancers are
preceded by viral infection (Parkin et al, 2006). Persistent infection
with high-risk human papillomavirus is considered requisite for
the development of certain anogenital cancers, including cervix,
and a subset of oropharyngeal cancers (Smith et al, 2007; Kreimer
et al, 2011a; Junor et al, 2012). Human papillomavirus (HPV) types
16 and/or 18 are implicated in the majority of cervical cancers
globally and local data would suggest these types are responsible
for approximately 80% of cervical cancers in Scotland (Cuschieri
et al, 2010).
HPV immunisation programmes are now implemented in many
countries, although the methods of delivery, uptake, gender policy
and monitoring systems vary (Markowitz et al, 2012), as does
the choice of vaccines which differ in valency, long-term
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immunogenicity and cross-protective ability (Romanowski, 2011).
In Scotland, a school-based vaccination programme for 12–13-
year-old girls, with an initial 3-year catch-up of 13–17 year olds,
commenced in September 2008 using the bivalent prophylactic
HPV vaccine, Cervarix . Uptake of vaccine in the routine cohort
(12–13 year olds) has been high, with levels sustained around 90%
(2010/11 uptake at August 2012—dose 1: 93%; dose 2: 92% and
dose 3: 90%) (Sinka et al, 2014). The 3-year catch-up campaign
attained a high uptake for all three doses among those vaccinated
in school, exceeding 80% (year 2 catch-up 2009/10—dose 1: 91%;
dose 2: 90% and dose 3: 85%), but a lower uptake of around 30%
was achieved in school leavers (year 2 school leavers 2009/10—
dose 1: 49%; dose 2: 41% and dose 3: 29%). In order to determine
the impact of HPV immunisation, a longitudinal national HPV
surveillance programme was set up in Scotland, a key element of
which involved yearly sampling and HPV genotyping of women
attending for their cervical screen at age 20.
Although HPV immunisation has been shown to reduce the
prevalence of HPV types 16 and 18 in the vaccine trials (Paavonen
et al, 2009; Wheeler et al, 2012), few studies have reported on the
impact of vaccination on type-specific HPV infection in national
programmes and to our knowledge, this is the first which assesses
the impact of the bivalent vaccination in relation to HPV
genoprevalence. The PATRICIA trial of Cervarix, a double-blind
randomised study of women aged 15–25 years, which considered
the efficacy of the vaccine against CIN2þ lesions and 6- and
12-month persistent infection with non-vaccine types, reported
end-of-trial data (Wheeler et al, 2012) of efficacy against HPV 31,
33 and 45 and a sub-group analysis of the Costa Rica Vaccine
randomised control trial suggested high efficacy for prevention of
infection with fewer than three doses (Kreimer et al, 2011b). If
such observations are corroborated at a population level, they will
convey additional public health and cost effectiveness benefits
(Kim et al, 2012).
Given the timing of the catch-up programme and the fact that
first screening invitation in Scotland is before aged 21, we are in a
position to assess post-vaccination HPV genoprevalence in women
aged 20–21 years according to their individual vaccination status
through the linkage of national databases for immunisation and
screening.
We aimed to compare HPV DNA type-specific prevalence in
unvaccinated and vaccinated 20–21 year olds to provide
information on the early impact of bivalent HPV vaccination
at the population level. By performing a comprehensive
genotyping assay for surveillance, as opposed to focusing on
HPV 16/18 only, we aimed to gain insights into cross-protection,
type replacement and unmasking by examining the occurrence
of multiple high-risk infections in young vaccinated women
(Tota et al, 2013).
MATERIALS AND METHODS
Sampling. We conducted a cross-sectional study that sampled
B1000 women aged 20–21 years attending their cervical screening
appointment over the period 2009–2012 to establish HPV
prevalence in vaccinated and unvaccinated women in Scotland.
Scotland has a population ofB5.2 million (National Records of
Scotland, 2012) and an organised cytology-based cervical screening
programme. Screening is currently recommended every 3 years for
women aged 20–60 years who are first invited to attend shortly
after their 20th birthday. All women eligible for cervical screening
are recorded in the national Scottish Cervical screening Call and
Recall System (SCCRS), a population-based information technol-
ogy system, which supports the programme and contains
pathology, recall and management information.
From 2009 to 2012, anonymised residual liquid-based cytology
(LBC) samples from young women aged 20–21 years were
collected from all 11 NHS cytopathology laboratories in Scotland,
which served the national programme. The inclusion of samples
from 2009–2010 before vaccinated girls were eligible for screening
allowed similar numbers of vaccinated and unvaccinated girls to be
compared as outlined in Kavanagh et al (2013). To achieve the
desired sample size of 1000 specimens per year, each laboratory
collected residual samples following cervical screening over a
2-month period from women aged 20–21 in that year; the exact
number from each laboratory was dictated by the size of the
population served by the laboratory, to ensure a geographically
representative sample. The collection periods from each laboratory
were staggered throughout the year, to balance workload in the
HPV Reference laboratory at the Royal Infirmary of Edinburgh.
Data and linkage. At the source cytology laboratories, all LBC
samples were labelled with an anonymous study identification
number and sent to the HPV Reference laboratory for HPV
genotyping. Separately, the study ID and the patient Community
Health Index reference (CHI, a unique national patient identifier)
were sent to the Information Services Division (ISD) of the
National Health Service in Scotland, who used CHI to link to
SCCRS and the national Scottish Immunisation call Recall System
(SIRS) and Child Health Schools Programme-System (CHSP-S)
data. Geographical data-zone (a small-area statistical geography see
(Scottish Government, 2005)) derived from the postcode of
residence, was attributed to each record and the Scottish Index
of Multiple Deprivation (SIMD) (a ranking of data-zones in terms
of multiple deprivation see (Scottish Government, 2012)) assigned.
All personal identifiable information was removed before passing
to Health Protection Scotland for analysis. Health Protection
Scotland used the study ID in these records to link to genotyping
results from the HPV Reference Laboratory.
HPV testing. Residual LBC samples were vortexed and a 1-ml
aliquot was used for extraction. Automated extraction for LBC
samples was performed used the MDX media Kit (Qiagen, Venlo,
Netherlands). HPV amplification and genotyping was performed
using the Multimetrix HPV Assay (Diamex, Heidelberg, Germany)
(Schmitt et al, 2006). This assay is based on luminex technology
and is capable of detecting 18 high-risk or putatively high-risk
types according to current IARC classification (Bouvard et al,
2009), specifically the 12 types in Group1 with ‘carcinogenic’ status
(HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59), the single type in
Group 2A with ‘probably carcinogenic’ status (HPV 68) and six
types from Group 2B with ‘possibly carcinogenic’ status (HPV 26,
53, 66, 70, 73, 82). In addition, five low-risk types are detected
(6, 11, 42, 43, 44).
Statistical analysis. The sample size of 2000 LBC specimens before
vaccination initiation (B1000 in each of 2009 and 2010) and 1000
per year thereafter provided at least a 99% power to detect a 15%
reduction in HPV prevalence at first cervical screen from 40 to 34%,
a 25% reduction in high-risk human papillomavirus prevalence at
first cervical screen from 25 to 19%, and a 40% reduction in HPV
16/18 prevalence at first cervical screen from 12 to 7%.
HPV type-specific prevalence and associated 95% confidence
intervals (CI) were calculated. Differences in HPV type-specific
prevalence of those receiving three doses of vaccination and no
vaccination were assessed via a z-test of two proportions using the
Bonferroni correction (significance level, a¼ 0.05/22) to account
for the multiple statistical testing conducted for the 22 non-vaccine
HPV types. As the analysis was powered to detect changes in HPV
types 16 and 18, their significance is assessed at a¼ 0.05. The
associations between the number of doses of vaccination (0, 1, 2 or
3 doses) and HPV outcome measure were assessed using logistic
regression adjusted for birth cohort year and deprivation score
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(assessed via the SIMD quintiles of the area of residence: one is
most deprived and five is least deprived) and evidence of a linear
change in positivity over the range of these variables was assessed
via a linear trend test. The interactions of birth cohort year and
number of doses and of SIMD and number of doses were
considered, but none found to be significant. HPV outcomes
considered were; HPV types 16 or 18; HPV types 31, 33 or 45; all
high-risk HPV (IARC Group 1 and Group 2A) excluding types 16,
18, 31, 33, 45 and finally; positivity for any HPV.
This analysis allowed us to examine whether there is a
statistically significant reduction of HPV 16/18, potential cross-
reactive types or other high-risk HPV types associated with
number of doses of vaccine received. In addition, we evaluated the
common pairings of HPV types detected and how these differ
between the vaccinated and non-vaccinated women by birth
cohort. In those with more than two high-risk types present, all
possible pairings were counted. We examined the robustness of our
conclusions on the effectiveness of the vaccine in reducing HPV
16/18 prevalence by conducting two sensitivity analyses: (i)
limiting the analysis to those born in 1991 and 1992 (this removes
the temporal bias that the unvaccinated are mainly those born in
1988–1990, but induces an out-of-school bias where the un-
vaccinated group is likely to be mainly those who had left school)
and (ii) excluding the unvaccinated in 1991 and 1992 (this limits
the out-of-school bias, but has unvaccinated and vaccinated
individuals compared over different time frames).
RESULTS
Overall, 4729 LBC samples were collected (B1000 per year,
distributed consistently (B20%) over the deprivation quintiles)
and tested for HPV with 4679 valid HPV test results obtained
(Table 1). Overall, 57.7% (95% CI 56.2, 59.1%) of samples were
positive for any HPV type and 47.4% (95% CI 46.0, 48.8%) were
positive for a high-risk HPV type. Due to eligibility, vaccination
status varied strongly by collection year with 38% of samples
collected in 2011 being from women who were vaccinated with
three doses of vaccination compared with 67% in 2012 (Table 1).
In years 2009 and 2010, samples are from those born in 1988, 1989
and 1990; the majority of whom are unvaccinated due to
ineligibility for the catch-up campaign. Overall, 23.4% of the
4729 LBC samples that were tested originated from fully vaccinated
individuals and 3.4% from partially vaccinated individuals.
The prevalence and 95% CI of each of the HPV types detected,
stratified by vaccine status, is shown in Figure 1. There was an
increase in the detection of high-risk HPV types 51 and 59 in those
who had received three doses of vaccination compared with the
unvaccinated group, but these increases were not statistically
significant. We found no decrease in HPV6/11 positivity across the
study years (2009: 4.2%, 2010: 5.2%, 2011: 5%, 2012: 5.5%) nor
with number of vaccine received (0 dose: 4.7%, 1 dose: 12.7%, 2
doses: 9.4%, 3 doses: 4.6%).
HPV positivity for vaccine HPV genotypes (HPV 16 or 18).
Vaccine was associated with a statistically significant reduction in
the prevalence of both HPV 16 and 18 (both Po0.0001) (Figure 1).
Overall, positivity for HPV 16 or 18 was 13.6% (95% CI 11.7, 15.8%)
in those receiving three doses of vaccine compared with 29.8% (95%
CI 28.3, 31.3%) in those who were unvaccinated (Table 2). This is
mirrored by the change over time with genoprevalence decreasing
from 28.8% (95% CI 26.7, 31.1%) in the 2009 samples to 16.7% (95%
CI 14.5, 19.2%) in the 2012 samples. Once adjusted for vaccination
status, there was no overall significant linear trend of birth cohort
year or SIMD on positivity for HPV 16 or 18 (P¼ 0.07 and 0.1,
respectively) (Table 3). There was a strong effect of vaccination for
those women vaccinated, with three doses showing a significant
reduction in HPV type 16 and 18 infection in the fully adjusted
model (Table 3). This effect is stronger when the unadjusted effect of
vaccination is considered: three doses (odds ratio (OR)¼ 0.37, 95%
CI 0.31, 0.45) and for two doses (OR¼ 0.61, 95% CI 0.38, 0.99).
Although one dose also showed a reduction in HPV type 16 and 18,
(OR¼ 0.88, 95% CI 0.48, 1.6) this was not statistically significant
(P¼ 0.68) in the unadjusted model.
HPV positivity for potentially cross-protective HPV types (HPV
31, 33 or 45). Along with the vaccine-specific types, the vaccine
Table 1. Yearly distribution of the number of samples collected (n¼ 4729) by number of vaccine doses received, the Scottish Index of Multiple
Deprivation (SIMD) and the number of samples with viable HPV results
Collection year
2009 2010 2011 2012
Total n samples 1672 1074 1005 978
n % n % n % n %
Number of doses
0 1653 98.9% 1012 94.2% 557 55.4% 241 24.6%
1 4 0.2% 7 0.7% 18 1.8% 26 2.7%
2 1 0.1% 7 0.7% 48 4.8% 50 5.1%
3 14 0.8% 48 4.5% 382 38.0% 661 67.6%
SIMD
1: Most deprived 386 23.1% 260 24.2% 235 23.4% 214 21.9%
2 388 23.2% 208 19.4% 190 18.9% 197 20.1%
3 335 20.0% 219 20.4% 185 18.4% 166 17.0%
4 271 16.2% 193 18.0% 201 20.0% 187 19.1%
5: Least deprived 292 17.5% 194 18.1% 194 19.3% 214 21.9%
Total samples with valid HPV results 1651 98.7% 1053 98.0% 1001 99.6% 974 99.5%
Abbreviations: HPV¼human papillomavirus; SIMD¼ Scottish Index of Multiple Deprivation.
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also afforded cross-protection against other high-risk types, with
statistically significant reductions in the prevalence between fully
vaccinated and unvaccinated groups for types HPV 31, 33 or 45
(P¼ 0.0002; P¼ 0.002; P¼ 0.001, respectively) (Figure 1). Overall
positivity for HPV 31, 33 or 45 was 6.8% (95% CI 5.5, 8.5%) in
those receiving three doses of vaccine compared with 13.1% (95%
CI 12.0, 14.3%) in those who were unvaccinated (Table 2). There is
a similar change over time with prevalence decreasing from 13.0%
(95% CI 11.5, 14.7%) in the 2009 samples to 8.1% (95% CI 6.6,
10.0%) in the 2012 samples. Those who had received three doses
had a significantly reduced odds of HPV types 31, 33 or 45
infection (adjusted OR¼ 0.53, 95% CI 0.38, 0.74) and those with
two doses had a reduced odds of infection, although this was not
statistically significant (adjusted OR¼ 0.55, 95% CI 0.26, 1.17). As
with HPV types 16 and 18, there was no significant effect of cohort
year on positivity for HPV types 31, 33 or 45 when adjusted for
vaccination status (P¼ 0.45) (Table 3). A significant linear effect of
SIMD (P¼ 0.005) remained for cross-protective type positivity
whereby women residing in the least deprived areas were less likely
to be infected than those in the most deprived (SIMD4 adjusted
OR¼ 0.66, 95% CI (0.49, 0.89), SIMD5 adjusted OR¼ 0.79, 95%
CI (0.59, 1.05)).
HPV positivity for non-vaccine high-risk types (any HR-HPV
excluding 16, 18, 31, 33, 45). Prevalence for any HR-HPV
excluding 16, 18, 31, 33 and 45 was 31.6% (95% CI 29.0, 34.4%) in
those receiving three doses of vaccine compared with 32.4% (95%
CI 30.9, 34.0%) in those who were unvaccinated (Table 2). There is,
however, an increase over time with prevalence rising from 29.1%
(95% CI 26.9, 31.3%) in the 2009 samples to 34.8% (95% CI
31.9, 37.9%) in the 2012 samples confounding the prevalence rates.
There was a significant linear trend in positivity with birth cohort
(P¼ 0.002) over and above the effect of vaccination. Those born in
1991 were 1.44 times (95% CI 1.12, 1.84) more likely to be infected
with a non-vaccine high-risk type than those born in 1988 and
similarly those born in 1992 were 1.53 times more likely (95% CI
1.16, 2.01). When adjusting for this, those receiving three doses of
vaccine had a reduced odds of infection with high-risk types
(OR¼ 0.81, 95% CI 0.66, 0.99) (Table 3). SIMD was not found to
have a significant relationship with high-risk HPV type positivity
excluding types 16, 18, 31, 33 and 45 (P¼ 0.48).
Overall HPV positivity (any HPV type). Overall HPV positivity
was generally unchanged over time—58.1% in 2009 and 58.0% in
2012 (Table 2) despite those who received three doses of
vaccination being less likely to be positive for any HPV (adjusted
OR¼ 0.66, 95% CI 0.54, 0.80) (Table 3). This is due to a general
increasing trend (P¼ 0.02) with birth cohort (positivity by year:
1988; 56.6%, 1989; 58.5%, 1990; 57.9%, 1991; 59.5%, 1992; 55%).
Compared with the reference year 1988, the first cohort vaccinated
Table 2. Prevalence of HPV 16 or 18, cross-protective types, high-risk HPV excluding HPV 16, 18, 31, 33 or 45 and any HPV stratified by the number of
doses received and the year of collection (N¼ 4679)
HPV 16 or 18 Cross-protective typesa
High-risk HPV excluding
vaccine and cross-protective
typesb
Any HPV
N
Number
positive
Pre-
valence
95% CI
Number
positive
Pre-
valence
95% CI
Number
positive
Pre-
valence
95% CI
Number
positive
Pre-
valence
95% CI
Number of doses
0 3418 1018 29.8% (28.3, 31.3)% 448 13.1% (12.0, 14.3)% 1108 32.4% (30.9, 34.0)% 2041 59.7% (58.1, 61.3)%
1 55 15 27.3% (17.3, 40.2)% 10 18.2% (10.2, 30.3)% 21 38.2% (26.5, 51.4)% 37 67.3% (54.1, 78.2)%
2 106 22 20.8% (14.1, 29.4)% 8 7.5% (3.9, 14.2)% 36 34.0% (25.6, 43.4)% 64 60.4% (50.9, 69.2)%
3 1100 150 13.6% (11.7, 15.8)% 75 6.8% (5.5, 8.5)% 348 31.6% (29.0, 34.4)% 587 53.4% (50.4, 56.3)%
Collection year
2009 1651 476 28.8% (26.7, 31.1)% 215 13.0% (11.5, 14.7)% 480 29.1% (26.9, 31.3)% 959 58.1% (55.7, 60.4)%
2010 1053 333 31.6% (28.9, 34.5)% 143 13.6% (11.6, 15.8)% 364 34.6% (31.8, 37.5)% 618 58.7% (55.7, 61.6)%
2011 1001 233 23.3% (20.8, 26.0)% 104 10.4% (8.6, 12.4)% 330 33.0% (30.1, 35.9)% 587 58.6% (55.6, 61.7)%
2012 974 163 16.7% (14.5, 19.2)% 79 8.1% (6.6, 10.0)% 339 34.8% (31.9, 37.9)% 565 58.0% (54.9, 61.1)%
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus.
a
Cross-protective types: HPV 31, 33 or 45.
b
High-risk HPV excluding vaccine and cross-protective types: HPV 35, 39, 51, 52, 56, 58, 59 or 68.
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Figure 1. (A) Proportion and 95% CI of anonymised 4679 LBC samples
in 2009–2012, which tested positive for each HPV type in
unvaccinated and fully vaccinated (three doses) women attending for
their cervical screen. (B) Difference in the proportion positive and
associated 95% CI for the difference by HPV type. With the exception
of types 16 and 18, the 95% CIs of the difference were corrected for
multiple testing using the Bonferroni correction. *statistically significant
change.
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as part of the catch-up campaign to attend screening (birth year 1991)
shows an increased adjusted odds of overall HPV positivity (OR¼ 1.44,
95% CI 1.14, 1.82). Those in the least deprived group were significantly
less likely to be positive (OR¼ 0.77, 95% CI 0.64, 0.92).
Sensitivity analyses. For the HPV 16/18 outcome, restriction of
the analysis to those in the 1991 and 1992 cohorts, thus removing
the temporal imbalance between the unvaccinated and vaccinated
groups, showed a stronger effect of vaccination than the baseline
analysis (adjusted OR¼ 0.34, 95% CI 0.25, 0.46) (Table 4).
Limiting the out-of-school effect in the unvaccinated (using all
year cohorts but excluding the unvaccinated in 1991 and 1992
birth cohorts) shows a weaker but still significant effect of
vaccination (OR¼ 0.65, 95% CI 0.44, 0.95).
Most common HPV pairings. Of those infected with a high-risk
HPV type, 50.0% (1123/2244) were infected with more than one
high-risk HPV type. Of these individuals, 27% had two types of
high-risk HPV present, 30% three, 22% four, 11% five and 10% had
more than five types. Infection with non-vaccine high-risk types
was common with 96.7% (1086/1123) having these types (not 16/
18) present. Excluding the vaccine and cross-reactive types, 86.1%
(968/1123) had another high-risk type present. Table 5 shows that
in unvaccinated women in all birth cohorts, HPV 16 was the most
common HPV type and was frequently detected concurrently with
types 52, 59 and 56. In the fully vaccinated women in the 1991 and
1992 birth cohorts, HPV 16 no longer dominates and pairings of
HPV 52 with HPV 56 and HPV 51 with HPV 56 are common
(13 and 12% of those with multiple high-risk HPV types,
respectively compared with 7.1 and 8.1% in unvaccinated
individuals in the same birth cohort). The pairing of HPV 39
with HPV 56 was found in 10.4% of those vaccinated in the 1991/
92 birth cohort with multiple high-risk types, compared with 4.7%
in those unvaccinated in the 1988/89/90 birth cohort.
DISCUSSION
This study has revealed the first definitive evidence of a large
reduction in HPV 16 and 18 in the target population after
introduction of a national bivalent HPV immunisation programme
and has also shown significant cross-protective effects for HPV 31,
33 and 45. In addition, we present evidence that two doses leads to
a reduction in HPV 16 and 18. However, the limited number of
individuals receiving two doses gives wide variability in the
estimate of this effect. Unlike Szarewski et al (2013), we found no
change in HPV 6 and 11 positivity over either the time frame of the
study or by vaccination status, although our results are not directly
comparable as those tested were not necessarily sexually naı¨ve at
vaccination.
In Scotland, the 3-year catch-up campaign targeting girls aged
13–17 years attained a high uptake for all three doses among
those vaccinated in school, exceeding 80%. However, there was
lower uptake of around 30% in school leavers (Sinka et al, 2014).
Nevertheless, the overall uptake of 66% in the catch-up cohort
compares very favourably with other countries, such as the
United States where 32% of girls aged 13–17 received the full
three-dose regimen (CDC, 2011). In Australia, where vaccine
uptake ranges from 50–70%, surveillance data have shown a
considerable decrease in vaccine-targeted genotypes (Tabrizi et al,
2012) and ecological studies have shown a demonstrable
reduction in cervical high-grade abnormalities associated with
the quadrivalent HPV vaccine (Brotherton et al, 2011). With high
levels of uptake, cervical screening commencement at age 20 and
the ability to link individual screening and vaccination records,
we are able, in Scotland, to demonstrate definitively the early
impact of bivalent HPV vaccine on HPV infections in the target
population.
Table 3. Fully adjusted odds of positivity for various groupings of HPV type by cohort year, number of doses received and SIMD
HPV 16 or 18 Cross-protective typesa
High-risk HPV excluding
vaccine and cross-
protective typesb
Any HPV
OR 95% CI
Linear
trend
P-value OR 95% CI
Linear
trend
P-value OR 95% CI
Linear
trend
P-value OR 95% CI
Linear
trend
P-value
Birth year 0.07 0.45 0.002 0.02
1988 1 — 1 — 1 — 1 —
1989 0.96 (0.79, 1.17) 0.82 (0.63, 1.06) 1.18 (0.97, 1.43) 1.08 (0.90, 1.29)
1990 1.06 (0.87, 1.29) 0.99 (0.76, 1.28) 1.40 (1.15, 1.70) 1.11 (0.93, 1.33)
1991 0.95 (0.73, 1.23) 0.89 (0.62, 1.26) 1.44 (1.12, 1.84) 1.44 (1.14, 1.82)
1992 0.72 (0.52, 0.98) 0.79 (0.52, 1.21) 1.53 (1.16, 2.01) 1.29 (0.99, 1.67)
Number of doses o0.0001 o0.0001 0.08 0.0009
0 1 — 1 — 1 — 1 —
1 0.95 (0.51, 1.76) 1.44 (0.70, 2.96) 1.09 (0.62, 1.91) 1.18 (0.66, 2.11)
2 0.68 (0.42, 1.12) 0.55 (0.26, 1.17) 0.90 (0.59, 1.39) 0.88 (0.58, 1.33)
3 0.43 (0.34, 0.55) 0.53 (0.38, 0.74) 0.81 (0.66, 0.99) 0.66 (0.54, 0.80)
SIMD quintile 0.1 0.005 0.48 0.009
1: Most deprived 1 — 1 — 1 — 1 —
2 0.89 (0.73, 1.08) 1.02 (0.79, 1.33) 1.01 (0.84, 1.21) 0.94 (0.79, 1.12)
3 0.89 (0.73, 1.10) 0.92 (0.70, 1.20) 1.04 (0.86, 1.26) 0.89 (0.74, 1.06)
4 0.94 (0.76, 1.15) 0.66 (0.49, 0.89) 1.01 (0.84, 1.23) 0.93 (0.77, 1.11)
5: Least deprived 0.80 (0.65, 0.98) 0.79 (0.59, 1.05) 0.92 (0.76, 1.12) 0.77 (0.64, 0.92)
Abbreviations: CI¼ confidence interval; HPV¼human papillomavirus; OR¼odds ratio; SIMD¼ Scottish Index of Multiple Deprivation. Bold values highlight the statistically significant
associations.
a
Cross protective types: HPV 31, 33 or 45.
b
High-risk HPV excluding vaccine and cross-protective types: HPV 35, 39, 51, 52, 56, 58, 59 or 68.
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The reduction in HPV 16/18 infection associated with two doses
is lower than the efficacy found in the Costa Rica randomised
control trial (Kreimer et al, 2011b). This is not unexpected as our
study was not powered to detect a two-dose effect. Those receiving
two doses did so only by default, leading to a limited dataset for
analysis. In addition, the HPV status of each girl at the date of
vaccination is unknown, whereas HPV naı¨ve girls can be identified
in the randomised control trial. Therefore, the effect we found may
be smaller than the true effect. The analysis of those in the
routinely vaccinated cohort, who were likely to be sexually naı¨ve at
vaccination, should present further evidence of the two-dose effect
when they enter the screening programme.
Table 4. Results of two sensitivity analyses for the HPV 16 or 18 outcome
Sensitivity analysis 1: limit to 1991 and 1992
cohorts
Sensitivity analysis 2: exclude unvaccinated in 1991 and 1992
cohorts
N % positive OR 95% CI N % positive OR 95% CI
Birth year
1988 — — — — 845 29.7% 1
1989 — — — — 1195 28.7% 0.96 (0.79, 1.17)
1990 — — — — 1025 34.0% 1.01 (0.83, 1.24)
1991 839 20.1% 1 — 562 15.3% 0.60 (0.38, 0.95)
1992 646 14.4% 0.79 (0.59, 1.05) 523 11.1% 0.43 (0.26, 0.69)
Number of doses
0 400 29.5% 1 — 3063 29.4% 1 —
1 41 21.9% 0.65 (0.29, 1.41) 55 27.3% 1.36 (0.70, 2.67)
2 85 21.2% 0.64 (0.37, 1.14) 106 20.8% 1.00 (0.57, 1.77)
3 959 12.2% 0.34 (0.26, 0.46) 1105 13.6% 0.64 (0.44, 0.95)
SIMD quintile
1: Most deprived 354 18.9% 1 — 995 26.7% 1 —
2 310 20.0% 1.07 (0.72, 1.59) 893 24.9% 0.90 (0.73, 1.11)
3 246 17.9% 0.96 (0.62, 1.47) 829 25.3% 0.91 (0.73, 1.12)
4 271 16.9% 1.01 (0.66, 1.55) 799 25.8% 0.98 (0.80, 1.22)
5: Least deprived 304 14.1% 0.76 (0.49, 1.17) 813 22.5% 0.82 (0.66, 1.03)
Abbreviations: CI¼ confidence interval; OR¼odds ratio; SIMD¼ Scottish Index of Multiple Deprivation. Bold values highlight the statistically significant associations.
Table 5. Most commonly occurring pairings of HPV types in those infected with multiple types, stratified by vaccine status and year
1988/89/90 cohorts
Unvaccinated
N¼771
1988/89/90 cohorts
Fully vaccinated
N¼27
1991/92 cohorts
Unvaccinated
N¼99
1991/92 cohorts
Fully vaccinated
N¼192
Rank
HPV
pairing
% of
samples
with
multiple
HR types 95% CI
HPV
pairing
% of
samples
with
multiple
HR types 95% CI
HPV
pairing
% of
samples
with
multiple
HR types 95% CI
HPV
pairing
% of
samples
with
multiple
HR types 95% CI
1 16 52 19.2 (16.6, 22.1) 16 56 22.2 (10.6, 40.8) 16 52 13.1 (7.8, 21.2) 52 56 13 (9, 18.5)
2 16 56 18.3 (15.7, 21.2) 16 52 18.5 (8.2, 36.7) 16 59 10.1 (5.6, 17.6) 51 56 12 (8.1, 17.3)
3 16 59 13.1 (10.9, 15.7) 39 59 14.8 (5.9, 32.5) 16 45 10.1 (5.6, 17.6) 39 59 10.4 (6.8, 15.5)
4 16 51 11.5 (9.5, 14.0) 16 59 14.8 (5.9, 32.5) 16 31 9.1 (4.9, 16.4) 51 59 9.4 (6.0, 14.3)
5 16 18 11.4 (9.4, 13.9) 16 51 14.8 (5.9, 32.5) 51 56 8.1 (4.2, 15.1) 16 51 9.4 (6.0, 14.3)
6 16 31 10.6 (8.7, 13.0) 16 18 14.8 (5.9, 32.5) 16 33 8.1 (4.2, 15.1) 16 59 8.9 (5.6, 13.7)
7 16 33 10.0 (8.1, 12.3) 51 52 11.1 (3.9, 28.1) 52 56 7.1 (3.5, 13.9) 51 52 8.3 (5.2, 13.1)
8 16 39 9.1 (7.2, 11.3) 16 45 11.1 (3.9, 28.1) 16 58 7.1 (3.5, 13.9) 16 52 8.3 (5.2, 13.1)
9 52 56 7.3 (5.6, 9.3) 51 59 7.4 (2.1, 23.4) 16 56 7.1 (3.5, 13.9) 56 58 7.8 (4.8, 12.5)
10 16 45 6.7 (5.2, 8.7) 39 51 7.4 (2.1, 23.4) 16 39 7.1 (3.5, 13.9) 39 56 7.8 (4.8, 12.5)
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus; HR¼ human risk. Those with incomplete doses are excluded from the analysis (three individuals from the 1988/89/90 birth
cohorts and 29 individuals from 1991/92 birth cohorts).
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There are theoretical concerns about high-risk HPV-type
replacement in those who are vaccinated (Tota et al, 2013) and in
our study, HPV 51, 52 and 56 emerged as the most prevalent
high-risk HPV types in the vaccinated population, although at
lower rates than those types which they replaced. Furthermore, it
is feasible that the types we describe as having ‘emerged’ have
actually always been present at low-viral load and have become
increasingly unmasked as a result of reduced competition for
assay resources.
In addition, commensurate with the reduction in HPV 16, 18,
31, 33 and 45, we also observed a decrease in cervical intra-
epithelial neoplasia (CIN) 2 and 3 in vaccinated cohorts through
analysis of colposcopy data (Pollock et al, 2013). Thus, although
the proportion found to be positive for any HPV type remains high
even in the immunised population, we have seen no evidence of
clinically significant high-risk type-replacement, at least in the
short term. This finding clearly needs to be explored further with
longer follow-up and associated clinical studies (Cuschieri et al,
2010; de Sanjose et al, 2010). Furthermore, the HPV immunisation
surveillance strategy in Scotland also involves the longitudinal
HPV typing of CIN2þ , which will be essential for the
quantification and monitoring of any clinically significant type
replacement.
The level of HPV positivity (including HR types) in vaccinated
women in this study reinforces the continuing need for cervical
screening, although it is important to highlight that a relatively
high proportion may have had sexual experience before
vaccination—given the age range which constituted the catch-
up population. One would expect the effect of vaccination to be
even more profound in the routine cohort of 12/13 year olds in
whom vaccine uptake is higher and this group will first present
for their cervical smear is 2015. Indeed, it is a limitation of our
study that we only sample those who present at routine screening.
Although overall screening uptake in Scotland is relatively high
(71.2% in 2012–13), it is considerably lower at 53.5% in those
aged 20–24 (National Services Scotland ISD, 2013). We have
previously reported HPV prevalence in a pre-vaccination group
who had defaulted from routine screening, using a postal testing
kits (urine or swab) survey (Sinka et al, 2011). Although
defaulters were more likely to come from deprived groups, they
were found to have similar patterns in HPV type prevalence
compared with attenders. However, a caveat of this analysis is
that different biospecimens were tested (urine and swabs vs LBC
samples) and results could not be directly compared. Further-
more, the poor response rate to the survey (13.2%) precluded
repetition for post-vaccination.
A further limitation of our analysis is that comparison of the
unvaccinated with the vaccinated groups is partially a temporal
comparison of the earlier cohorts with the later cohorts, as virtually
all of the earlier cohorts are unvaccinated and most of the latter are
fully vaccinated. If HPV positivity was decreasing over this time
frame then this would lead to an apparent reduction in HPV
prevalence among the vaccinated women, even if the vaccine had
no effect. However, temporal analysis showed overall HPV
positivity stayed constant over the 4 years sampled. We also
explored this issue specifically using a sensitivity analysis, which
indicated a stronger effect of vaccination when the analysis was
restricted to the later cohorts. This implies that it is very unlikely
that there has been a coincidental reduction in HPV prevalence
over the time frame. It should be noted that by solely using the
1991 and 1992 cohorts, the unvaccinated group are mainly those
who have left school which may contribute to an over-estimation
of the effect. Furthermore, we found a significant reduction in the
odds of non-vaccine high-risk type HPV in the vaccinated group,
whereas a non-effect might have been expected. This indicates that
those vaccinated are less likely to have been exposed to HPV before
vaccination than girls from the unvaccinated group. A previous
study of HPV prevalence in 12–19 year olds in Scotland
(O’Leary et al, 2011) (where a self-sample was used),
showed that 9% of 16–18 year olds, who were at an urban school,
were HPV positive, compared with 38% of those who had left
school and were in further education. Although we cannot assess
when women in that cohort left school and fully adjust for it, the
potential over-estimation in vaccine effect has been partially
controlled for by examining unvaccinated women overall five birth
cohorts to give a more representative balance of those in and out of
school. The potential scale of the confounding effect is considered
by sensitivity analysis, which demonstrated that excluding the
unvaccinated females in 1991 and 1992 led to a reduced
but still statistically significant reduction for HPV 16/18. This
suggests that reduction in prevalence of HPV vaccine types is
unlikely to be solely attributable to the confounding influence of
age at leaving school.
Although vaccine was offered to all girls from age 13–17
during the catch-up programme, there was a statistically
significant effect of deprivation on HPV positivity which
existed at the baseline examination of HPV prevalence, where
the most deprived girls were more likely to have HPV
infection (Kavanagh et al, 2013). This differential is still present
in this post-vaccination assessment. While the mean
uptake of vaccine in the catch-up cohort was 66% for all three
doses, it should be noted that there was a disparity in uptake
between those who stayed on at school (80%) and those
who left school but attended their GP surgery (30%), with those
who stayed on at school more likely residing in the least deprived
areas (Sinka et al, 2014). Even within the school-delivered
programme, those residing in the least deprived areas were more
likely to be vaccinated with three doses than those in the most
deprived areas. These data reinforce the need for young women to
attend cervical screening on a regular basis, as it is women from
more deprived areas who are disproportionately affected by
cervical malignancy (Baker and Middleton, 2003). It is somewhat
reassuring that the analysis of vaccine uptake in the routine
cohorts aged 12/13 does not show the same pattern, with uptake
of vaccine being both high and equitable across deprivation
classes (Sinka et al, 2014).
In order to estimate the impact of HPV vaccine, it is important
to ascertain the effect of the vaccination programme on the whole
population, with particular focus on the age group where such
changes will be initially observed. We have shown here that
vaccination with the bivalent HPV vaccine is associated with a
significant reduction in vaccine-specific HPV types in the catch-up
cohort. Furthermore, the vaccine appears to confer protection
against infection with other high-risk HPV types 31, 33 and 45. It
is also encouraging that there appears to be a lesser protective effect
of receiving two doses, albeit the majority of these were delivered in
months 0 and 1. These encouraging findings add to the evidence
presented in clinical studies although these employed a two-dose
regimen several months apart (Roteli-Martins et al, 2012). Our
data provide a tantalising insight into the early impact of HPV
vaccination at the population level and are very encouraging for
countries with national programmes where high-vaccine uptake
has been achieved.
ACKNOWLEDGEMENTS
Monitoring and evaluation of the HPV immunisation programme
in Scotland is funded by the Scottish Government. The associated
research is partially funded by the Chief Scientist Office
(CZH/4/528). We also acknowledge Katy Sinka’s earlier work at
Health Protection Scotland in setting up the HPV surveillance
programme.
BRITISH JOURNAL OF CANCER Reduction of HPV 16/18 in target population
2810 www.bjcancer.com |DOI:10.1038/bjc.2014.198
REFERENCES
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F,
Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. WHO
International Agency for Research on Cancer Monograph Working Group
(2009) A review of human carcinogens—Part B: biological agents. Lancet
Oncol 10: 321–322.
Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM (2011)
Early effect of the HPV vaccination programme on cervical abnormalities in
Victoria, Australia: an ecological study. Lancet 377: 2085–2092.
Baker D, Middleton E (2003) Cervical screening and health inequality in
England in the 1990s. J Epidemiol Community Health 57: 417–423.
CDC (2011) National and state vaccination coverage among adolescents aged
13 through 17–United States, 2010. MMWR 60: 1117–1123.
Cuschieri K, Brewster DH, Williams ARW, Brewster DH, Williams AR, Millan D,
Murray G, Nicoll S, Imrie J, Hardie A, Graham C, Cubie HA (2010)
Distribution of HPV types associated with cervical cancers in Scotland and
implications for the impact of HPV vaccines. Br J Cancer 102: 930–932.
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B,
Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA,
Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C,
Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M,
Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Mene´ndez C,
Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E,
Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A,
Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A,
Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J,
Andu´jar M, Castellsague´ X, Sa´nchez GI, Nowakowski AM, Bornstein J,
Mun˜oz N, Bosch FX. Retrospective International Survey and HPV Time
Trends Study Group (2010) Human papillomavirus genotype attribution in
invasive cervical cancer: a retrospective cross-sectional worldwide study.
Lancet Oncol 11: 1048–1056.
Junor E, Kerr G, Oniscu A, Campbell S, Kouzeli I, Gourley C, Cuschieri K
(2012) Benefit of chemotherapy as part of treatment for HPV DNA-
positive but p16-negative squamous cell carcinoma of the oropharynx.
Br J Cancer 106: 358–365.
Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock KG, Cubie H,
Donaghy M, Robertson C (2013) Estimation of HPV prevalence in young
women in Scotland; monitoring of future vaccine impact. BMC Infect Dis
13: 519.
Kim J, Lowy D, Smith-McCune KK, Melief CJM (2012) The Value of HPV
Vaccination. Nat Med 18: 28–29.
Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC,
Solomon D, Jime´nez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L,
Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R. CVT Vaccine
Group (2011a) Efficacy of a bivalent HPV 16/18 vaccine against anal HPV
16/18 infection among young women: a nested analysis within the Costa
Rica Vaccine Trial. Lancet Oncol 12: 862–870.
Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M,
Gonza´lez P, Solomon D, Jime´nez S, Schiller JT, Lowy DR, Quint W,
Sherman ME, Schussler J, Wacholder S. CVT Vaccine Group. (2011b)
Proof-of-principle evaluation of the efficacy of fewer than three doses of
831 a bivalent HPV16/18 vaccine. J Natl Cancer Inst 103: 1444–1451832.
Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS,
Brotherton JM (2012) Human papillomavirus vaccine introduction–the
first five years. Vaccine 30(Suppl 5): F139–F148.
National Records of Scotland (2012) 2011 Census: First Results on Population
Estimates for Scotland - Release 1A. http://www.scotlandscensus.gov.uk/
documents/censusresults/release1a/rel1asb.pdf (accessed 04/07/13).
National Services Scotland ISD (2013) Scottish Cervical Screening Programme
Statistics 2012-13 https://isdscotland.scot.nhs.uk/Health-Topics/Cancer/
Publications/2013-08-27/2013-08-27-Cervical-Screening-report.pdf?
65131777525[accessed 05/02/14].
O’Leary MC, Sinka K, Robertson C, Cuschieri K, Lyman R, Lacey M, Potts A,
Cubie HA, Donaghy M (2011) HPV type-specific prevalence using a urine
assay in unvaccinated male and female 11- to 18-year olds in Scotland.
Brit J Cancer 104: 1221–1226.
Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H,
Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G,
Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA,
Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M,
Dubin G (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-
adjuvanted vaccine against cervical infection and precancer caused by
oncogenic HPV types (PATRICIA): final analysis of a double-blind,
randomised study in young women. Lancet 374: 301–314.
Parkin DM (2006) The global health burden of infection-associated cancers
in the year 2002. Int J Cancer 118: 3030–3044.
Pollock K, Potts A, Love J, Cuschieri K, Cubie H, Kavanagh K, Robertson C,
Cruickshank M, Donaghy M (2013) Early effect of the HPV bivalent
vaccine on high-risk HPV prevalence and high-grade cervical
abnormalities in Scotland. Proc EuroGINhttp://www.eurogin.com/2013/
images/pdf/EUROGIN-2013-Abstracts-Part-2.pdf[accessed 05/01/14].
Romanowski B (2011) Long-term protection against cervical infection with
human papillomavirus. Review of currently available vaccines. Hum
Vaccin 7(2): 161–169.
Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T,
Sanchez N, Geeraerts B, Descamps D (2012) Sustained immunogenicity and
efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of
follow-up. Hum Vaccin Immunother 8(3): 390–397.
Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T (2006)
Bead based multiplex genotyping of human papillomaviruses. J Clin
Microbiol 44: 504–512.
Scottish Government (2005) Scottish Neighbourhood Statistics Guide. http://
www.scotland.gov.uk/Publications/2005/02/20697/52626. Accessed online
28 October 2013.
Scottish Government (2012) Scottish Index of Multiple Deprivation. http://
www.scotland.gov.uk/Topics/Statistics/SIMD. Accessed online 28 October
2013.
Sinka K, Kavanagh K, Gordon R, Love J, Potts A, Donaghy M, Robertson C
(2014) Achieving high and equitable coverage of adolescent HPV vaccine
in Scotland. J Epidemiol Community Health 68: 57–63.
Sinka K, Lacey M, Robertson C, Kavanagh K, Cuschieri K, Nicholson D,
Donaghy M (2011) Acceptability and response to a postal survey using
self-taken samples for HPV vaccine impact monitoring. Sex Transm Infect
87(7): 548–552.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM
(2007) Human papillomavirus type distribution in invasive cervical cancer
and high-grade cervical lesions: a meta-analysis update. Int J Cancer 21:
621–632.
Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D,
Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De
Carvalho NS, Castro-Sanchez M, Castellsague´ X, Poppe WA, De Sutter P,
Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA,
Bajo-Arenas J, Harper DM, Torne´ A, David MP, Struyf F, Lehtinen M,
Dubin G (2013) Efficacy of the HPV-16/18 AS04-adjuvanted vaccine
against low-risk hpv types (PATRICIA randomized trial): an unexpected
observation. J Infect Dis 208(9): 1391–1396.
Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS,
Coutle´e F, Villa LL, Franco EL. Epidemiologic approaches to evaluating
the potential for human papillomavirus type replacement postvaccination.
Am J Epidemiol (2013) 178(4): 625–634.
Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B,
Bateson D, McNamee K, Garefalakis M, Garland SM (2012) Fall in human
papillomavirus prevalence following a national vaccination program.
J Infect Dis 206: 1645–1651.
Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P,
Salmero´n J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR,
Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe
WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D,
Struyf F, Dubin G, Lehtinen M. HPV PATRICIA Study Group (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against
cervical infection and precancer caused by non-vaccine oncogenic HPV
types: 4-year end-of-study analysis of the randomised, double-blind
PATRICIA trial. Lancet Oncol 13: 100–110.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 3.0 Unported License.
Reduction of HPV 16/18 in target population BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.198 2811
